Major Scottish Hospital Adopts Steriwave
Ondine Biomedical Inc.
30 July 2026
30 July 2026
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine", or "the Company")
UK's Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection
Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, together with its UK distribution partner, Mölnlycke Health Care, is pleased to announce that NHS Golden Jubilee is the first hospital in Scotland to adopt Steriwave® nasal photodisinfection. The milestone brings Steriwave into the surgical pathway at the UK's largest hip and knee replacement centre, supporting the hospital's commitment to advancing the Scottish Government's 2026 health objectives and reinforcing the role of rapid, non-antibiotic infection prevention in protecting surgical capacity and supporting high-quality patient care.
NHS Golden Jubilee performs approximately 30% of Scotland's hip and knee replacements and plays a central role in delivering elective orthopaedic care for patients across the country. The Scottish Government's health objectives place significant emphasis on prevention, planned-care capacity and more effective use of Scotland's National Treatment Centres, which are intended to support recovery, reduce waiting times and increase elective surgical capacity.
Steriwave aligns with these priorities by making nasal decolonisation a five-minute, clinician-administered, point-of-care treatment immediately before surgery. The treatment uses a light-activated antimicrobial agent and red light to rapidly reduce harmful pathogens in the nose, a known reservoir for bacteria, viruses and fungi associated with surgical site infections ("SSIs"). By reducing reliance on multi-day home-based nasal decolonisation regimens, Steriwave provides greater procedural certainty and supports antimicrobial stewardship through a non-antibiotic approach.
SSIs can have a major impact on patients and hospital resources, increasing length of stay, delaying recovery and placing additional pressure on surgical and wider bed capacity. UK research linking National Joint Registry and Hospital Episode Statistics data reveals that patients requiring revision surgery for a prosthetic joint infection following primary hip replacement incur roughly £33,000 in additional inpatient and day-case costs over the subsequent five years, compared with patients whose replacement is not complicated by infection.[1] At a high-volume centre such as NHS Golden Jubilee, where standard elective joint replacements typically involve an average hospital stay of 2.4 days,[2] reducing SSIs can have a meaningful impact on patient recovery, hospital capacity and the efficient use of specialist surgical resources.
Professor Christopher Gee, Consultant Orthopaedic Surgeon at NHS Golden Jubilee, said:
"Our primary mission is to ensure the highest standards of safety for patients undergoing joint replacement surgery by consistently implementing evidence-based best practices. Preventing surgical site infections is a critical component of our approach, and our team actively uses advanced technologies to minimise risk. By integrating nasal photodisinfection into our infection-prevention bundle, we offer an efficient, nurse-led solution that enhances patient outcomes and optimises healthcare resources."
Carolyn Cross, CEO of Ondine Biomedical, commented:
"As Scotland advances its health strategy, we are proud to support NHS Golden Jubilee in bringing rapid, non-antibiotic nasal photodisinfection into its surgical pathway. In high-volume elective surgery, every infection prevented protects both patients and capacity. Revision surgery for a prosthetic joint infection can add tens of thousands of pounds in additional treatment costs and months of further care over a patient's recovery, resources that would otherwise support new patients coming through the pathway. Steriwave puts control of a critical part of infection prevention in the hands of clinical teams at the point of care, helping protect patients and supporting surgical capacity across the NHS."
Lina Karlsson, EVP Antiseptics for Mölnlycke, added:
"At Mölnlycke, our vision is a world without healthcare-associated infections, and our partnership with Ondine and the Steriwave technology is an important step towards that goal. We are proud to collaborate with NHS Golden Jubilee and to support its efforts to prevent surgical site infections and improve patient outcomes. We believe the success of this initiative can help accelerate the adoption of effective patient decolonisation practices across the NHS and beyond."
For healthcare providers in the UK, Steriwave is available through Ondine's distribution partner, Mölnlycke Health Care, a global leader in medical solutions. For more information contact: Healthcare Professionals Contact or antiseptics.uk@molnlycke.com or call +44 0800 917 4918.
-- ENDS --
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
Strand Hanson Limited (Nominated & Financial Adviser) |
|
|
James Harris, Richard Johnson, Imogen Ellis |
+44 (0)20 7409 3494 |
|
Peel Hunt LLP (Broker & Joint Financial Adviser) |
|
|
James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
|
5654 & Company (Financial PR and IR Adviser) |
ondinebiomedical@5654.co.uk |
|
Matthew Neal, Chris Gardner, Melissa Gardiner |
+44 0791 7800 011 +44 0775 7697 357 |
About Mölnlycke Health Care
Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those associated with multidrug-resistant organisms.
Ondine's lead product, Steriwave®, is authorised for nasal decolonisation in Canada, the UK, and certain other international markets. In the United States, the technology has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration and recently completed enrolment in its Phase 3 clinical trial.
The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
U.S. Regulatory Status and Clinical Data Disclaimer
Ondine's light-activated antimicrobial technology, commercially available as Steriwave® in certain jurisdictions, is not approved, cleared, or commercially available for sale or clinical use in the United States and is limited by U.S. law to investigational use only.
References to clinical outcomes in this release should be interpreted in the context of the specific studies or real-world evaluations described and do not imply regulatory approval for any particular indication.
[1] Matharu GS, Berryman F, Judge A, et al. What are the inpatient and day case costs following primary total hip replacement of patients treated for prosthetic joint infection: a matched cohort study using linked data from the National Joint Registry and Hospital Episode Statistics. BMC Med. 2020;18:349. (link)
[2] Public Health Scotland. Scottish Arthroplasty Project: Figure 9.1. Edinburgh: Public Health Scotland; 2025. (link)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.